Business
Boehringer Ingelheim & PRTC Immuno-oncology Collab
Boehringer Ingelheim & PRTC Immuno-oncology Collab.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 4120W PureTech Health PLC 17 April 2019 \n\n17 April 2019\n \nPureTech Health plc \n \nPureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform \n \nPureTech Health to receive up to $26 million in upfront payments, research support, and preclinical milestones and is eligible to potentially receive more than $200 million in milestones, in addition to royalties\n \nCollaboration will initially focus on developing Boehringer Ingelheim's novel immuno-oncology product candidates \n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that it has entered into a research collaboration with Boehringer Ingelheim to develop novel product candidates for an undisclosed number of targets by leveraging PureTech's proprietary lymphatic targeting technology for immune modulation. Under terms of the agreement, PureTech Health will receive up to $26 million, including upfront payments, research support, and preclinical milestones, and is eligible to receive more than $200 million in development and sales milestones, in addition to royalties on product sales. The collaboration will initially focus on applying PureTech's lymphatic targeting technology to an immuno-oncology product candidate designated by Boehringer Ingelheim.\n \n\"We see great promise in leveraging PureTech's platform to target the lymphatic system and deliver therapeutic candidates directly to the lymph nodes responsible for priming, educating and proliferating immune cells,\" said Clive Wood, PhD, global head of discovery research at Boehringer Ingelheim. \"The approach is a potentially powerful tool for modulating the immune system and may allow us to improve efficacy and reduce systematic toxicities through precise targeting.\"\n \nThe partnership leverages the potential of the proprietary lymphatic targeting platform that PureTech Health is developing through its internal R&D division. The approach harnesses the gut's lipid transport mechanisms to enable oral administration and transport of drug candidates directly through the gut-draining lymphatic vasculature, also bypassing first pas...